Fiche société
Qilu Pharmaceutical Co., Ltd.
Traitements, essais et publications liés.
Traitements7programmes
Essais1liés
Publications18liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Ia:QLS2404 high doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 Max doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 middle doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 very low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ib:QLS2404 low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | À vérifier | China | À vérifier |
| Ia:QLS2404 very low doseThis study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. | Lupus | Phase 1 | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ia:QLS2404 very low dose | Lupus | Phase 1 | NCT07751315 | A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases | NOT_YET_RECRUITING |
Publications
18| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ib:QLS2404 low dose | How to utilise the limited supply of vaccines for Mpox control in Thailand among high-risk GBMSM. | Infectious Disease Modelling | ||
| Ib:QLS2404 low dose | Temperature as a Co-stressor modulating the ecotoxicity of 3,4-dichloroaniline in Daphnia magna. | Aquatic toxicology (Amsterdam, Netherlands) | ||
| Ib:QLS2404 low dose | Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1,2,4-triazine moieties as potential c-MET targeting anticancer agents. | Bioorganic chemistry | ||
| Ia:QLS2404 Max dose | An open-label, two-cohort, phase 1a/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma. | European journal of cancer (Oxford, England : 1990) | ||
| Ia:QLS2404 Max dose | Pharmacokinetic Drug Interaction Studies of Limnetrelvir with Midazolam and Itraconazole in Healthy Participants. | Clinical drug investigation | ||
| Ia:QLS2404 high dose | Application of 18-glycyrrhetinic acid Fluorescent probes in cell imaging. | Journal of enzyme inhibition and medicinal chemistry | ||
| Ia:QLS2404 middle dose | Transradial versus transfemoral access for diagnostic cerebral angiography: Lesion-specific radiation metrics and outcomes. | Clinical neurology and neurosurgery | ||
| Ia:QLS2404 very low dose | Pain perception and patient tolerance to intra-articular ozone-oxygen injections in the treatment of temporomandibular joint osteoarthritis. | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery | ||
| Ia:QLS2404 very low dose | Comprehensive evaluation of GdO reinforced polyhydroxybutyrate as a hybrid neutron-gamma shielding material: Spatial dose mapping, photon buildup factors and neutron capture performance under primary and secondary radiation. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine | ||
| Ib:QLS2404 low dose | Low-Dose Buprenorphine Initiations During Opioid and Sedative Weaning in Mechanically Ventilated Neurocritical Care Patients: A Retrospective Pilot Cohort Study. | Neurocritical care | ||
| Ib:QLS2404 low dose | Safety and efficacy of recombinant botulinum toxin type A (Eveotox®) in patients with post-stroke upper limb spasticity: Results from a Phase Ib/II clinical trial. | Toxicon : official journal of the International Society on Toxinology | ||
| Ia:QLS2404 Max dose | A randomized controlled phase Ia clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of tofacitinib tartrate cream (HZ-J001) in healthy Chinese subjects. | Frontiers in pharmacology | ||
| Ia:QLS2404 Max dose | Formulation-dependent differences in systemic glutathione availability: Comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | ||
| Ia:QLS2404 high dose | Assessment of Ultraviolet-C Inactivation of and in the Anesthesia Workspace. | Mayo Clinic proceedings. Innovations, quality & outcomes | ||
| Ia:QLS2404 middle dose | Examining the Association Between Internet Addiction and Nonsuicidal Self-Injury Among Chinese Middle School Students: Prospective Cohort Study. | Journal of medical Internet research | ||
| Ia:QLS2404 middle dose | Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales - A retrospective study. | Journal of the neurological sciences | ||
| Ia:QLS2404 very low dose | Soil contamination by metals and radionuclides in missile-affected areas: radiological risk assessment and phytotoxic effects on wheat plants. | Environmental geochemistry and health | ||
| Ia:QLS2404 very low dose | Effects of acute and long-term exercise modalities and doses on brain-derived neurotrophic factor in patients with stroke: a Bayesian network meta-analysis. | Frontiers in systems neuroscience |